Predicting kidney and liver damage in cancer patients receiving chemotherapy

预测接受化疗的癌症患者的肾脏和肝脏损伤

• 批准号: 10027358
• 金额: $ 72.68万
• 依托单位: EVERGREEN HEALTH SOLUTIONS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10027358
• 关键词: Predicting; kidney; liver; damage; cancer

Chemotherapy is the treatment of disease using chemical substances, commonly used to treat cancer.Chemotherapy is often cytotoxic and two common risks relate to kidney and liver damage. Affected patients may require delays or changes to treatment and even treatment suspension.Whilst only <10% of patients will encounter kidney and or liver damage, current best practice requires monitoring for all patients with regular blood testing. There is currently no way to stratify risk in individual patients.**The vision for this project is to accurately predict the risk of kidney and liver damage in patients receiving chemotherapy**. The result of this prediction will mean low risk patients can be saved unnecessary trips to hospital for blood tests and monitoring whilst high risk patients can receive more appropriate management.To date, computer scientists at Durham University, working closely with pharmacists at University College London Hospital (UCLH) have developed a machine learning algorithm to accurately predict liver and kidney function.Results have been shared at a number of key conferences and stakeholder events and there is strong clinical interest in utilising this algorithm in clinical practice.**The main area of focus for this project will be a prospective diagnostic accuracy study**. This will produce a commercial proof-of-concept (POC) software application that will allow the validated algorithm, produced by Durham University academics, to be used in live clinical practice.Key objectives will include:* Develop POC software to allow algorithm to be tested in a live clinical setting* Rapid iterative development of POC to enable commercial launch* Data collection to validation algorithm* Identification of third-party software interface opportunities (particularly chemotherapy e-prescribing systems)* Development of commercialisation planCurrently ~375k patients are diagnosed with cancer every year in the UK, with ~28% of these expected to receive chemotherapy for their primary disease[[1]][0].With similar rates of cancer incidence across the Western world, this innovation could personalise care for millions globally. https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence[0]: #_ftn1[1]: #_ftnref1

化疗是利用化学物质治疗疾病，常用来治疗癌症。化疗通常具有细胞毒性，两种常见的风险与肾脏和肝脏损伤有关。受影响的患者可能需要延迟或改变治疗，甚至暂停治疗。虽然只有<10%的患者会出现肾脏和/或肝脏损害，但目前的最佳做法要求对所有患者进行定期血液检测。目前还没有办法对个别患者的风险进行分层。**该项目的愿景是准确预测化疗患者的肾和肝损害风险**。这一预测的结果将意味着低风险患者可以省去不必要的前往医院进行血液检查和监测，而高风险患者可以得到更适当的管理。迄今为止，杜伦大学的计算机科学家与伦敦大学学院医院（UCLH）的药剂师密切合作，开发了一种机器学习算法，可以准确预测肝肾功能。结果已经在一些重要会议和利益相关者活动上分享，并且在临床实践中使用该算法具有强烈的临床兴趣。**该项目的主要重点领域将是前瞻性诊断准确性研究**。这将产生一个商业概念验证（POC）软件应用程序，该应用程序将允许由杜伦大学学者开发的经过验证的算法用于现场临床实践。主要目标将包括：*开发POC软件以允许算法在现场临床环境中进行测试* POC的快速迭代开发以实现商业发布*数据收集以验证算法*识别第三方软件接口机会（特别是化疗电子处方系统）*开发商业化计划目前，英国每年约有37.5万名患者被诊断患有癌症。其中约28%的人预计将因原发疾病接受化疗。由于西方世界的癌症发病率相似，这一创新可以为全球数百万人提供个性化护理。https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence[0]: #_ftn1[1]: #_ftnref1